ISPOR REAL-WORLD EVIDENCE TRANSPARENCY COLLABORATIVE – THE CASE FOR STUDY REGISTRATION
Author(s)
Speakers: Lucinda Orsini, DPM, MPH, Associate Chief Science Officer, ISPOR, Lawrenceville, NJ, USA Marc Berger, MD, Vice President, Real World Data and Analytic, Pfizer, Inc., New York, NY, USA; Shirley Wang, PhD, Assistant Professor in Medicine, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; David L. Van Brunt, PhD, MS, BA, Head, Evidence and Analytics, Health Economics and Outcomes Research, AbbVie, Chicago, IL, USA; William Crown, PhD, Chief Scientific Officer, Optum Labs, Cambridge, MA, USA; Gregory Daniel, PHD, MPH, Deputy Director, Policy, Duke-Robert J. Margolis, MD, Center for Health Policy, Washington, DC, USA
Presentation Documents
Real-world data (RWD) and real-world evidence (RWE) are becoming more accepted as ways to generate evidence for decision making. However, there are still questions about the quality and statistical rigor of the evidence provided by observational secondary studies. One way to help determine the quality of these types of studies is to have more transparency of the hypothesis and methods used to collate and analyze the data. This forum will present the current efforts of an ISPOR-led collaborative intending to move the needle on observational secondary study registration as a means to increase transparency. The progress and deliberations of this collaborative will be reviewed and discussed here, including concrete recommendations for next steps which will form the basis of a whitepaper. Feedback from the audience will be encouraged and collected to help inform the collaborative as it moves forward.
Conference/Value in Health Info
2019-05, ISPOR 2019, New Orleans, LA, USA